Vertex Pharmaceuticals is diversifying from its cystic fibrosis dominance into pain and other markets. Check out our ...

Vertex Pharmaceuticals' products are constantly in high demand. The company's portfolio should help drive revenue growth for a while. It also has an exciting pipeline that will help it diversify ...

The past decade has been a game-changing one for Vertex Pharmaceuticals (NASDAQ ... helping the company grow product revenue to more than $11 billion in the 2024 full year. It's likely these ...

Vertex and Alnylam are seen as most resilient ... Morningstar reports that with the U.S. importing approximately $200 billion in pharmaceuticals in 2024, a 10% tariff could have cost the ...

Edward Morrow Atkinson III, Executive Vice President and Chief Technical Operations Officer at Vertex Pharmaceuticals ... within the pharmaceutical industry. The company's upcoming product ...

Vertex Pharmaceuticals (Nasdaq ... Casgevy’s build-out and further launches of new products in 2025 and 2026, Vertex now seems set for steady profitable growth. There is no dividend.

Vertex Pharmaceuticals is stopping development of VX-264, an experimental cell therapy/medical device treatment for type 1 diabetes, after an early look at Phase 1/2 data fell short of efficacy goals.

Zimislecel, Vertex’s investigational fully differentiated islet cell therapy with standard immunosuppression, is in the Phase 3 portion of the ...

In the latest trading session, Vertex Pharmaceuticals (VRTX) closed at $484.01, marking a +0.11% move from the previous day. This change outpaced the S&P 500's 4.84% loss on the day. At the same ...

Vertex Pharmaceuticals generated more than $11 billion in product revenue last year thanks to its dominance in cystic fibrosis treatment. Progress in that specialty area and two key drug approvals ...